ONE KENDALL SQUARE. BUILDING 600-700, CAMBRIDGE, MA
Announces First Cohort Dosed in Phase 1/2 Clinical Trial (ANCHOR) for KRRO-121
Other Events
Reports Second Quarter 2026 Financial Results and Provides Corporate Update
Korro Bio, Inc. Elects Directors Nessan Bermingham and Rachel Meyers
Investor Presentation
Reports First Quarter 2026 Financial Results and Provides Corporate Update
Annual Report to Security Holders
Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
Q2
Q1
FY 2025
Q3
FY 2024
Prospectus filed pursuant to Rule 424(b)(3)
Effectiveness Notice
Prospectus filed pursuant to Rule 424(b)(5)
Registration Statement for Securities Offered under a Shelf Registration
Registration Statement for Securities to be Offered to Employees
Definitive Proxy Statement
Additional Proxy Materials
PRE 14A
Statement of Changes in Beneficial Ownership
Notice of Proposed Sale of Securities
Submission Upload
Correspondence
Post-Effective Amendment to Registration Statement